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Objectives: Utility is a health state value that is influenced by disease, treatments 
or policy. The use of the EuroQOL five dimension questionnaire (EQ-5D) has been 
frequently implemented to measure utility in cardiovascular (CV) disease. The objec-
tive of the analysis was to report baseline EQ-5D estimates in high CV risk patients 
with hypercholesterolemia not optimally treated with maximally tolerated statins 
± other lipid-lowering treatments. MethOds: Baseline EQ-5D was calculated via 
pooled analysis of the ODYSSEY FH I, FH II, HIGH FH, COMBO I, COMBO II and LONG 
TERM registered clinical trials to assess the efficacy and safety of alirocumab for 
lowering low-density lipoprotein cholesterol (LDL-C) in high CV risk patients. High 
CV risk patients included: history of recent acute coronary syndrome (ACS); coro-
nary heart disease (CHD); ischemic stroke (IS); peripheral artery disease (PAD); and 
heterozygous familial hypercholesterolemia (HeFH). The five EQ-5D item scores were 
estimated and the UK tariff was applied. Results were calculated for each patient 
segment and were not mutually exclusive, i.e. patients may have had a history of 
> 1 of the above-mentioned CV conditions. Results: 4,203 patients with baseline 
EQ-5D were included. Mean age was 59 years and 63% were male. Results by patient 
segment were: ACS 0-12 months, age 56 years, utility 0.844; ACS 12-24 months, age 
59 years, utility 0.858; CHD, age 61 years, utility 0.851; IS, age 64 years, utility 0.797; 
PAD, age 63 years, utility 0.771; HeFH, age 53 years, utility 0.905. cOnclusiOns: 
Unadjusted results suggest that the mean baseline EQ-5D for all high CV risk 
patients ranges from 0.771 for PAD patients to 0.905 for HeFH patients. These results 
are important for informing the utilities of high CV risk patients.
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Objectives: Pulmonary arterial hypertension (PAH) is a chronic, life-threatening 
disease affecting overall health status and quality of life. Riociguat has demon-
strated a consistent benefit as a treatment for PAH within one year of treatment. 
This analysis sought to assess the long-term impact of riociguat on patient-
reported health status over the 2-year PATENT-2 study. MethOds: In the PATENT-1 
study, PAH patients were randomized to receive placebo, riociguat individual dose 
titration up to 2.5 mg TID (three times a day), or riociguat fixed dose titration at 
1.5mg TID. PATENT-2 is an open-label extension phase where all patients received 
riociguat up to 2.5mg TID. Patient reported health status in PATENT-1 (baseline 
and week 12) and PATENT-2 (long term extension (LTE) week 12, and LTE months 
6, 9, 12 and 24) was assessed using the EQ-5D. Responder analyses were performed 
to evaluate EQ-5D scores in the context of clinical outcomes (6-minute walk dis-
tance (6MWD) and WHO functional class). EQ-5D utility scores and response dis-
tributions were analysed. Results: In the total sample patients demonstrated 
an increase in mean EQ-5D utility scores between baseline (mean 0.682, n= 392) 
and month 24 (mean 0.733, n= 221); a trend mirrored by improvement in EQ-5D 
VAS score from baseline (mean 62.5, n= 388) to month 24 (mean 72.3, n= 219). At 
month 24 a general improvement in all EQ-5D domains, except self-care, was 
observed regardless of participants’ previous treatment arm. Responder analyses 
indicated that patients with greater improvement in 6MWD (> 40m) at week 12 had 
higher mean scores than those with less improvement (< 40m) at all time-points 
throughout the two year follow-up. Furthermore, patients with better functional 
capacity according to WHO classification (class I/II) had higher EQ-5D utility scores 
than those with worse capacity (class III/IV). cOnclusiOns: Results demon-
strate the long-term positive impact of riociguat on PAH patients’ reported health 
status.
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Objectives: Chronic thromboembolic pulmonary hypertension (CTEPH) is a severe 
disease with high mortality, thus significantly affecting patient quality of life and 
health status. Almost 40% of patients are unsuitable for surgery and approximately 
34% experience recurrent disease post-surgery. Riociguat has demonstrated clini-
cal benefit for CTEPH patients within one year of treatment. This analysis sought 
to assess the long-term impact of riociguat treatment on patient-reported health 
status. MethOds: CTEPH patients were randomized to placebo or riociguat dose 
titration up to 2.5mg TID (three times a day) in the CHEST-1 study. CHEST-2 is an 
open-label extension phase where patients from CHEST-1 received riociguat up to 
2.5mg TID. Patient reported health status was assessed using the EQ-5D in both 
CHEST-1 (baseline and week 16), and CHEST-2 (long term extension (LTE) week 12, 
and LTE months 6, 9, 12 and 24). Responder analyses were performed to put EQ-5D 
scores into context with clinical outcomes (6-minute walk distance (6MWD) and 
WHO functional class). EQ-5D utility scores and response distributions were sum-
marised. Results: In the total sample patients demonstrated an increase in mean 
EQ-5D utility score between baseline (mean 0.646, n= 235) and month 24 (mean 
0.717, n= 97); a trend mirrored by improvement in EQ-5D VAS score from baseline 
(mean 56.5, n= 236) to month 24 (mean 71.4, n= 97). At month 24 there were similar 
proportions of patients in the riociguat and former placebo groups reporting ‘No 
problems’ in all EQ-5D domains indicating improved health. A responder analysis 
tigated the benefits of extended treatment with tinzaparin (LMWH) versus war-
farin for the prevention of recurrent VTE events in cancer patients experiencing 
a VTE. We aim to describe the baseline patient-reported health-related quality-
of-life (HRQL) and the impact of having experienced a VTE within this very large 
data set in cancer-associated thrombosis. MethOds: The CATCH trial randomised 
900 patients with active cancer from 32 countries. EQ-5D-3L data were collected 
at baseline and every month for seven months. We chose to apply the UK prefer-
ence weight set and explored the baseline data which captured the acute phase 
of VTE. Exploratory univariate analyses tested the effects of covariates including 
age, gender, metastatic status, primary site of cancer, ECOG status, and history of 
VTE. Results: At baseline, in the acute phase of VTE, patients reported quite poor 
HRQL (mean EQ-5D score: 0.52) with no difference between the treatment arms. 
Women reported significantly worse HRQL than men (0.49 and 0.56), whereas there 
was no significant difference across age groups. Patients who had both sympto-
matic DVT and symptomatic PE reported the worst mean score (0.46). Patients with 
higher ECOG score had lower HRQL, whereas similar mean scores were seen for 
metastatic status and varying scores across different cancers (brain, breast, lung, 
hepatobiliary, upper GI, lower GI, genitourinary, prostate, gynaecologic, haemato-
logical). Latin American and Asian patients reported lower scores of HRQL than 
patients in other regions. cOnclusiOns: Compared to EQ-5D estimates reported 
in the literature for cancer patients, data from this large trial of cancer associated 
thrombosis shows that experiencing VTE has a significant additional impact on 
HRQL. Women quality of life seems to be affected the most.
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Objectives: To study the demographic details of hypertensive & diabetic patients 
and their knowledge, attitude and practices (KAP) regarding their illness. MethOds: 
We examined KAP on hypertension and diabetes in a sample of 50 adult hyper-
tensive patients and 50 adult diabetic patients aged above 20 years. KAP’s were 
assessed during the period from October 2014 to January 2015. Results: Altogether 
50 hypertensive and 50 diabetic patients were enrolled in the study. Most of the 
respondents in the KAP on hypertension were aged between 31- 40 years(56%) and 
94% of the participants knew that hypertension is the disease state whereas in KAP 
on diabetes 46% are aged in between 31-40 years of age ,88% of participants know 
that the Diabetes is a condition in which the body contains increased levels of blood 
glucose . We observed poor score in attitude and practice part of the questionnaire. 
It concludes that the responders had good knowledge but poor attitude and practice 
towards the diseases. Repeated reinforcement and motivation along with health 
education will definitely bring about a positive change in attitude and practices 
among the patients. cOnclusiOns: We conclude that the motivation and counsel-
ling stressing the importance of life-style modifications and self-management is 
required for the patients suffering with chronic diseases like hypertension and dia-
betes. Patient counselling by the clinical pharmacist can play a vital role in imparting 
education to the diabetic and hypertensive patients.
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Objectives: In the UK, abdominal aortic aneurysms (AAA) affect 5-10% of men and 
1.5% of women > 65yrs. Previous reports of symptoms and quality of life (QoL) were 
conflicting when no AAA-specific tools were available. The present work aimed 
to design three AAA-specific questionnaires: the Aneurysm-Dependent Quality of 
Life Questionnaire (Aneurysm-DQoL), Aneurysm Symptom Rating Questionnaire 
(Aneurysm-SRQ), and Aneurysm Treatment Satisfaction Questionnaire (Aneurysm-
TSQ). MethOds: 41 patients with AAA from five NHS Trusts participated in focus 
group discussions of experiences of AAA. This information guided inclusion of items 
in the questionnaires, supported by the clinical experience of vascular surgeon 
co-authors and an existing pool of items from existing questionnaires developed 
by CB and colleagues for other conditions. Initial questionnaire drafts were refined 
through 13 one-to-one patient interviews. Results: The new Aneurysm-DQoL 
has 23 life domains (16 from an existing item bank, 5 modified, 2 new) that were 
identified as being important to the QoL of patients with AAA. The Aneurysm-SRQ 
is a 44-Item measure, which assesses a wide range of physical and psychological 
symptoms. (16 bank, 14 modified, 14 new). The Aneurysm-TSQ has 11 items (2 bank, 
6 modified, 3 new): 7 are suitable pre- and post-intervention and 4 are suitable post-
intervention only. The qualitative work revealed several previously unrecognised 
issues for patients with AAA, confirming the importance of AAA-specific measures. 
These included the impact on QoL of self-imposed restrictions on activity, nota-
bly patients’ avoidance of sexual activity (rather than poor sexual function). Also, 
follow-up scans were reassuring rather than worrying for patients. cOnclusiOns: 
The detailed development process confirmed that the new tools have good face and 
content validity for patients with AAA. Item banks were valuable; few new items 
were needed for Aneurysm-DQoL and Aneurysm-TSQ. Psychometric analyses are 
being reported elsewhere. The questionnaires are ready for wider clinical use and 
further validation.
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which could be attributed to various pharmacological interventions. The critical 
appraisal concluded that the studies were of moderate quality. cOnclusiOns: 
The majority of included RCTs used HF-specific questionnaires, to measure QoL. 
From 2009 onwards, the use of KCCQ increased compared to MLHFQ and KCCQ was 
administered to a comparatively larger study population. Thus, QoL data retrieved 
from studies using KCCQ are considered to be more representative of the real world. 
The inconsistency in reporting of QoL results in RCTs limited comparison of the 
treatment impact on QoL
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Objectives: In Germany, apheresis is indicated for patients on maximally tolerated 
lipid lowering therapy (max LLT) with uncontrolled low density lipoprotein (LDL) 
levels over 12 months. The current application process restricts patients’ access 
to apheresis although no other treatments are available. Despite its burdensome 
nature and invasiveness, this procedure offers an additional LDL lowering when max 
LLTs are insufficient. This psychodrama market-research aimed to understand the 
patients’ perception of apheresis and how apheresis affects daily living. The core 
concept is to ‘ask without asking’. MethOds: Eligible patients had severe hyper-
cholesterolemia, ≥ 1 cardiovascular event, apheresis, and were ≤ 72 years of age. 
The conducted workshops focused on the following topics: 1) disease perception 2) 
perception of apheresis 3) anticipated impact of new therapies on patients’ quality 
of life (QoL). Psychodrama techniques were used to investigate and gain insight into 
the perceptional and emotional world of the patients. A QoL questionnaire (SF-36) 
was applied before (QoL with apheresis) and after the workshop (imagination of 
QoL with a new therapy option). Results: Four workshops took place in October 
2014 in Munich (n= 2), Berlin and Frankfurt. The average age was 63 years (N= 26) 
and patients had broad experience with apheresis. The assessment on the disease 
perception led to feedbacks such as, “It doesn’t hurt and that is bad!”, “My whole 
life changed” or “The fear is in my head!”. Perception of apheresis was ambiguous 
revealing cons (“invasive”, “time-consuming”) and pros (“life-saver”, “effective”). The 
SF-36 evaluation demonstrated an increase in the overall QoL state for the majority 
of patients (n= 20). CONCLUSIONS: Apheresis is seen as burdensome but neces-
sary. Without alternatives, apheresis is considered important by patients, however, 
patients are eager to try new therapies offering more efficacious disease control 
and thereby avoidance of apheresis.
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Objectives: To quantify preference weights (including willingness to pay = WTP) 
for attributes of a bedside pharmacogenetic test for the CYP2C19*2 allele to permit 
personalization of antiplatelet therapy in patients with acute coronary syndromes 
(ACS). MethOds: This internet-based survey tool comprised of: patient demo-
graphics, a decision board and choice sets. Context was provided by way of a deci-
sion board that offered three treatment alternatives for hypothetical ACS patients, 
one of which offered pharmacogenetic testing. Respondents choosing the pharma-
cogenetic option were provided with 8 choice sets; each with two alternatives. Each 
alternative consisted of three attributes, each with three levels. Attributes (levels) 
included: how sample was taken (cheek swab, finger prick or draw blood); turna-
round time for results (1 hour, 3 days, 1 week), and cost expressed as an additional 
annual insurance premium in Canadian dollars (C$)(C$0, C$2, C$10). A full factorial 
design was implemented. A conditional logit regression model was used to analyze 
the responses. The survey was disseminated to randomly selected respondents in 
Ontario (Canada), stratified by age, gender and education. Results: Results are 
generalizable to the Ontario population. Among 328 respondents who completed 
an informed consent for the survey, 219 chose the pharmacogenetic test option 
providing 3472 observations. Exponential coefficients (standard errors) and p val-
ues are as follows: Turnaround; 1 week = 0.089 (0.13) p< 0.0001, 3 days = .243 (0.113) 
p< 0.0001, Sample extraction; finger prick = 1.043 (0.104) p= 0.683, cheekswab = 
1.140 (0.100) = 0.19, cost = 0.63127 (0.032) p< 0.001. WTP in additional annual insur-
ance premiums is C$5.18 for one hour over a 7 day turnaround time and C$3.06 
over a 3 day turnaround. cOnclusiOns: Respondents were 11 times as likely to 
choose a 1 hour turnaround time, and tended to prefer the cheekswab method. 
An incremental WTP was observed for more expedient sample turnaround 
time.
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Objectives: Heart failure (HF) is an important public health problem that 
depletes a large quantity of health resources. Around 2% of the adult popula-
tion in developed countries suffers from HF. The high prevalence of HF in Spain, 
around 5%, is mostly determined by its population’s progressive ageing. This study 
describes the impact of HF on hospital admissions, length of stay, hospitalization 
confirmed that patients who had a greater improvement in 6MWD (> 40m) at week 
12 of the study had higher mean scores than those with lower improvement (< 40m). 
Furthermore, patients with better functional ability according to WHO classifica-
tion had higher EQ-5D utility scores than those with lower ability. cOnclusiOns: 
Results demonstrate the positive impact of riociguat on patient-reported health 
status among CTEPH patients.
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Objectives: Hypertension has few subjective symptoms and its treatment must 
be continued long term, as patients may stop visiting the hospital regularly and 
give up on lifestyle improvements. Therefore, the effective and brief coaching-style 
intervention program is essential in community pharmacies. The objective of this 
study was to investigate the effect of intervention by community pharmacists on the 
awareness of continuing treatment among patients with hypertension. MethOds: 
This study was designed as a cluster-randomized controlled trial with a 3-month 
intervention period. The subjects comprised adult patients with essential hyper-
tension who had been taking antihypertensive medication for at least 3 months. 
Patients in the intervention group underwent a motivational interview with a phar-
macist lasting around 3 minutes each time they received a prescription, while those 
in the observation group were provided with usual care. Both groups’ patients were 
provided with a home blood pressure monitoring device and pedometer. The study 
outcome was awareness of the continuation of regular hospital visits, healthy diet, 
and appropriate exercise, rated on a 10-point scale from “Extremely important” to 
“Not at all important.” Results: Responses were obtained from 114 patients at 55 
pharmacies (intervention group: 28, observation group: 27). that had enrolled in the 
study A comparison of awareness before and after intervention showed that only 
awareness of regular hospital visits had improved in the observation group (p = 
0.03), whereas in the intervention group, awareness of both regular hospital visits 
(p = 0.04) and appropriate exercise (p = 0.02) showed improvement. cOnclusiOns: 
The findings of this study revealed that intervention by community pharmacists 
may contribute to raising awareness of the need to continue exercise. This result 
implies that pharmacist can improve patients’ ability to chronic disease manage-
ment.
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Objectives: To measure the quality of life (QoL) of patients 12 months after an 
acute coronary syndrome (ACS) MethOds: PGRx-3 are multiusers, multi-countries, 
prospective Real World Datasets assembled to describe disease risk factors, burden 
of disease, disease management, treatment patterns and patient quality of life; they 
are also used for the study of the effectiveness and relative risk of medicines. More 
than 15 disorders have been studied with the PGRx methodology and extensive 
validation studies have been published. Patients are recruited by their physician in 
France, UK, Italy, Germany, Spain and in the US, and interviewed and/or fill a self-
questionnaire. The French PGRx ACS registry has involved 218 investigators since 
October 2013, 90% of them being cardiologists. To date, 3725 patients have been 
included. The self-reported QoL was completed at 12 months, using the EQ-5D and 
SF-12 in a sample of 619 patients who had their follow-up visit between February 
and May 2015. Results: 75% of patients were male, mean age at ACS was 67 years 
[SD= 11], and 71% had a first-lifetime ACS. 12 months after the ACS, the mean score 
of EQ-5D was 0.72 [SD= 0.24], the less favourable ratings were for pain and restriction 
in mobility, considered as “severe” in 10% and 12% of patients, respectively. Using 
the SF-12, 65% patients rated a “good” health, 80 (47%) had limited mobility, and 
70% declared some pain interfering with normal life. cOnclusiOns: 12 months 
after ACS, patients declared a rather good QoL, despite daily limited mobility, pain 
and discomfort.
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Objectives: Systolic heart failure (HF), is a progressive condition carrying a high 
risk of mortality, hospitalisation and having a significant detrimental impact on 
quality of life (QoL). Current therapies indicated for use in this patient population 
demonstrated beneficial effects on QoL, however the magnitude of effects remain 
debatable. This review was performed to identify QoL instruments (disease spe-
cific and generic) used in systolic heart failure, to estimate the impact of various 
pharmacological interventions. MethOds: Publications resulting from Randomised 
controlled trials (RCTs) as well as post-hoc analysis of RCTs from 1996 to October 21, 
2014 were selected using pre-defined inclusion criteria. Critical appraisal of trials 
was performed using the NICE risk of bias tool. Results: A total of 37 publications 
from 33 RCTs met the inclusion criteria. The main HF-specific QoL instruments used 
were the Minnesota Living with Heart Failure Questionnaire (MLHFQ) (8,004 patients) 
in 19 trials and the more recent Kansas City Cardiomyopathy Questionnaire (KCCQ) 
(12,101 patients) in four trials. The generic EQ-5D (VAS) was used in three trials 
whereas SF-36 was used in two trials. Four studies also reported correlations 
between end point changes in morbidity or mortality and change in QoL. Significant 
changes in QoL were found in 9 active and 5 placebo-controlled trials respectively, 
